by Damon Race | Jan 23, 2023 | Press
January 23, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced that it has expanded the Company’s management team and board of directors with the...
by Damon Race | Jun 7, 2022 | Press
June 7, 2022 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced the award of a $250,000 Strategic Research Loan (SRL) from the North Carolina...
by Damon Race | Nov 2, 2021 | Press
Preclinical data provide quantitative evidence of GENV-HEM’s ability to achieve phenotypic correction in animal models of hemophilia, independent of the presence of any clotting factor inhibitors. Estimated 95,000 patients in the U.S. and Europe represent...
by Damon Race | Mar 3, 2021 | Press
March 3, 2021 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a gene therapy company developing a safe, effective, and durable, single infusion treatment for all types of hemophilia with or without inhibitors, today announced the expansion of...
by Damon Race | Jan 19, 2021 | Press
January 12, 2021 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a gene therapy company developing a safe, effective and durable, single infusion treatment for all types of hemophilia with or without inhibitors, today announced the...
by daniel | Oct 30, 2020 | Press
GeneVentiv Therapeutics and University of North Carolina Chapel Hill Enter License Agreement RALEIGH, NC, November 2, 2020 — GeneVentiv Therapeutics, Inc. has entered into a license agreement with the University of North Carolina Chapel Hill for a patent pending, gene...
Recent Comments